In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Heart failure patients who stop taking medications are at risk for hospitalization

Session Poster session 1 Saturday 08:30 -17:30

Speaker Barbara Riegel

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P247

Authors : B Riegel (Philadelphia,US), GJ Knafl (Chapel Hill,US)

15 views

Authors:
B Riegel1 , GJ Knafl2 , 1University of Pennsylvania - Philadelphia - United States of America , 2University of North Carolina - Chapel Hill - United States of America ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 51

Purpose: Medication nonadherence predicts hospitalization in HF patients, but the phase of nonadherence most responsible is unclear (initiation, implementation, or discontinuation). Our purpose was to determine which phase is most responsible and to identify characteristics of patients in that phase.

Methods: Adults with chronic HF were enrolled from 3 clinic sites in the US. Medication adherence over 6-months was measured using medication-event monitoring system (MEMS). Medication initiation was defined as percent of time to first dose taken, discontinuation as percent of time after the last dose was taken, and implementation as the period between. Clinical data were abstracted from medical records by nurses. Trail Making Test B was used to measure complex attention; higher scores indicate worse attention. Higher scores on the American National Adult Reading Test (ANART) indicate higher premorbid intellect. Higher scores on the PHQ-9 indicate more depression. Higher scores on the Charlson Comorbidity Index indicate more chronic conditions. All analyses used adaptive modeling methods.

Results: Of the 218 patients with MEMS data, 6 (2.8%) did not initiate their medicines immediately (median 13% of time in study). All 218 patients had some implementation phase data with most (53.7%) completing the full study. 83 (38.1%) patients met criteria for early discontinuation (≥3.1% of the full study period). Early discontinuation was the best predictor of hospitalization (risk factors shown in table). Area under the curve was very good for this model (0.75).

Conclusion: Discontinuing the medication regimen risks hospitalization in adults with chronic HF. Complex patients with multiple chronic conditions, numerous medications, depression, problems with attention and analytic skills may consider stopping medicines if not assisted to integrate the regimen into their lives.

interaction term 1

interaction term 2

variable

risk factor

variable

risk factor

group n (%)

OR

95% CI

Charlson

≥ 4 vs. < 4

TMTB score

≥ 94 vs. < 94

33 (15.1)

6.31

2.58-15.4

ANART

≤ 37 vs. > 37

months of dx

≤ 21 vs. > 21

36 (15.1)

4.77

2.04-11.2

Meds #

≥ 7 vs. < 7

PHQ-9 total

≥ 9 vs. < 9

25 (11.50

5.96

2.18-16.3

ANART

≤ 37 vs. > 37

pulse

≤ 58 vs. > 58

24 (11.0)

3.86

1.45-10.3

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are